11099 Torrey Pines Rd. Suite 290
About Janux Therapeutics
At Janux, we are developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. We believe that combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient responses.
8 articles with Janux Therapeutics
Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Janux Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
Janux Therapeutics, Inc. today announced that Janux management will participate in three upcoming investor conferences.
Janux Therapeutics, Inc. today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.
Janux Therapeutics, Inc. announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
Janux Therapeutics, Inc. today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit